Taletrectinib: clinical trials recruiting now
3
Recruiting trials
3
Conditions studied
10
US states with sites
3
Countries
FDA drug label
- FDA-approved
- Yes. Taletrectinib appears in the FDA drug-label database. Marketed as IBTROZI.
FDA-approved use
IBTROZI ® (taletrectinib) is indicated for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) [see Dosage and Administration ( 2.1 )] . IBTROZI is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC). ( 1 )
Phase breakdown
Phase 3 2
Not applicable 1
Conditions being studied
| Condition | Trials |
|---|---|
| Lung cancer · Taletrectinib for Lung cancer | 3 |
| Non Small Cell Lung Cancer | 2 |
| Non-small Cell Lung Cancer (NSCLC) | 1 |
Recruiting trials involving Taletrectinib
- A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
- Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
- Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases
Common questions
Is Taletrectinib FDA-approved?
Yes, marketed as IBTROZI.
How many recruiting trials involve Taletrectinib?
3 recruiting trials across 3 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.